Cagrilintide + Semaglutide 5mg + 5mg Blend

Cagrilintide + Semaglutide — 5mg + 5mg research blend

This listing is for one research vial labeled with 5mg cagrilintide and 5mg semaglutide, for a combined listed content of 10mg. The amounts identify each component separately; they are not a ready-to-use concentration or instructions for administration. The SRP stomach-and-brain graphic represents the two signaling systems investigated in the literature. This blend has its own catalogue entry because it contains two ingredients, and should not be confused with a vial containing only cagrilintide or only semaglutide.

Cagrilintide is a long-acting amylin analogue, while semaglutide is a GLP-1 receptor agonist. Research on their combination examines the interaction of these hormone-related pathways rather than treating the two substances as a single peptide. A randomized phase 1b study published in 2021 evaluated concomitant administration, including pharmacokinetics, tolerability and exploratory metabolic outcomes. This provides context for studying the pair, but the protocol, preparations and monitored clinical setting differ from an SRP research blend. The published findings are not product-specific validation of this vial. Read the 2021 concomitant-administration study.

Later research includes a phase 3a trial in adults with overweight or obesity and type 2 diabetes. That trial used a defined study formulation, prespecified eligibility criteria and a structured follow-up period. Its relevance here is to document that the two-component approach has been investigated in a controlled research program. Results obtained with a sponsor’s characterized formulation cannot establish that a separately supplied premixed material has the same composition, stability, exposure or performance. The distinction between a published trial product and the item offered on this page remains essential. Read the 2025 phase 3a study.

For evaluation of a premixed research material, ingredient identity and the stated amount of each component are separate questions from compatibility over time. A study of coadministration does not, on its own, demonstrate storage stability when two compounds are combined in one vial. The shared SRP mechanism chart therefore describes the two receptor systems and the scope of combination research without claiming proven synergy for this exact formulation. The product label’s milligram amounts and nominal 3ml capacity should not be interpreted as a clinical formulation, a dosing recommendation or an assurance of equivalence to a medicine.

Documentation and research use

The SRP COA review, chromatography, mass-spectrometry and lot-traceability graphics are educational examples, not analytical measurements from these vials. They do not establish purity, identity, sterility or clinical suitability. Match any report to the selected strength and the actual lot before drawing conclusions about the material. Follow supplier documentation for handling and storage. For research use only; not for human or veterinary use, diagnosis or treatment.